Thursday, 18 April 2024

Australia's most trusted
source of pharma news

Thursday, 18 April 2024
Listen to this story 

Dear Minister, funding must change

Posted 28 March 2024 AM

Peak cancer groups have hand-delivered a message to Health and Aged Care Minister Mark Butler calling for urgent expanded access to the PD-1/PD-L1 inhibitor class of drugs for more than 3500 Australians.

The appeal for a new, so-called 'pan tumour' approach to reviewing and funding cancer medicines, follows two submissions made to the PBAC last year by MSD and BMS which would see their blockbuster drugs Keytruda and Opdivo (plus BMS' CTLA-4 inhibitor Yervoy) automatically listed on the PBS at the point of TGA registration.

To see the whole article, please login

Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (4)

Sales & Customer Relations (20)

Clinical & Medical, R&D (15)

Regulatory, Pharmacovigilance & QA (7)

Devices (1)

Other (32)

Email this article to a friend

Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.


Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.


Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).


You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.


You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.